Nicole Lou is a Medical Reporter at MedPage Today. She covers a range of topics within medicine and healthcare, including drugs and medication, health news, and consumer health, with a particular interest in alternative medicine and wellness. Nicole's work has been featured in MedPage Today, Knowledia, RamaOnHealthcare, and MSN.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Nicole Lou's coverage heavily focuses on healthcare and pharmaceuticals, particularly topics related to cardiac health, medical research, treatments, and controversies in the healthcare industry. Her articles often cite data extensively.
She would likely welcome pitches that offer access to new or exclusive data related to developments in cardiac health, medical research breakthroughs or controversies within the healthcare industry. Additionally, she may be interested in expert commentary from professionals with direct experience or involvement in the subjects covered.
Given her focus on citing data extensively, sources who can provide robust and reliable statistics as well as evidence-based insights will be of particular interest to her.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Nicole Lou
A diagnosis of myocardial infarction (MI) now falls into one of three types: primary, secondary, or procedure-related, based on the new Fifth
By: Nicole Lou
— ASPIRED trial tested a strategy of extended ECG monitoring starting in the emergency department
Once again, a beta-blocker failed to prove beneficial in people with chronic obstructive pulmonary disease (COPD) without cardiovascular disease in a randomized trial.
A broad population of people with chronic obstructive pulmonary disease (COPD), current and former smokers alike, experienced fewer exacerbations
TIMBERLINE study shows good safety and sweat chloride reductions with triple combo CFTR modulator
Phase II study finds benefits with multi-targeting of inflammatory pathways
Nighttime light exposure linked to subclinical findings and clinical events
In cystic fibrosis, vanzacaftor-tezacaftor-deutivacaftor (VTD; Alyftrek) showed great potential for modifying the progression of disease in young children, according to the TIMBERLINE study.
The unique dual inflammation blockade of investigational lunsekimig showed promise for moderate-to-severe asthma in the phase II AIRCULES study.
The concept that there are cardiovascular harms of nighttime light exposure gained greater credence with a large new study.
